Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma: a systematic literature review

References

• Küppers R. The biology of Hodgkin’s lymphoma. Nat Rev Cancer. 2008;9(1):nrc2542.
   Web of Science ®Google Scholar
• Eichenauer DA, Aleman BMP, Andre M, et al. Hodgkin lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv19–iv29.
   PubMed Web of Science ®Google Scholar
• Weber AL, Rahemtullah A, Ferry JA. Hodgkin and non-Hodgkin lymphoma of the head and neck: clinical, pathologic, and imaging evaluation. Neuroimaging Clin N Am. 2003 Aug;13(3):371–392.
   PubMed Web of Science ®Google Scholar
• Rathore B, Kadin ME. Hodgkin’s lymphoma therapy: past, present, and future. Expert Opin Pharmacother. 2010;11(17):2891–2906.
   PubMed Web of Science ®Google Scholar
• DeVita VT Jr., Carbone PP. Treatment of Hodgkin’s disease. Med Ann District Columbia. 1967 Apr;36(4):232–234. passim.
   PubMedGoogle Scholar
• Skoetz N, Will A, Monsef I, et al. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev. 2017 May 25;5:CD007941.
   PubMed Web of Science ®Google Scholar
• Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med. 2003 Jun 12;348(24):2386–2395.
   PubMed Web of Science ®Google Scholar
• Evens AM, Hutchings M, Diehl V. Treatment of Hodgkin lymphoma: the past, present, and future. Nature Clin Pract Oncol. 2008;5(9):543–556.
   PubMedGoogle Scholar
• Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol. 2005 Oct 20;23(30):7614–7620.
   PubMed Web of Science ®Google Scholar
• Canellos GP, Duggan D, Johnson J, et al. How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? J Clin Oncol. 2004 Apr 15;22(8):1532–1533.
   PubMed Web of Science ®Google Scholar
• Federico M, Luminari S, Pellegrini C, et al. Brentuximab vedotin followed by ABVD ± radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study. Haematologica. 2016 Apr;101(4):e139–41.
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Holkova B, Goldschmidt J, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015 Dec 24;126(26):2798–2804.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA news release. FDA expands approval of Adcetris for first-line treatment of Stage III or IV classical Hodgkin lymphoma in combination with chemotherapy. Available at: https://wwwfdagov/news-events/press-announcements/fda-expands-approval-adcetris-first-line-treatment-stage-iii-or-iv-classical-hodgkin-lymphoma . 2018.
   Google Scholar
• Takeda. European Commission Approves ADCETRIS® (brentuximab vedotin) with AVD, the first new treatment in decades for adults with previously untreated CD30+ stage IV Hodgkin lymphoma. News release Feb 2019. Available at https://wwwtakedacom/newsroom/newsreleases/2019/european-commission-approves-adcetris-with-avd-for-adults-with-previously-untreated-cd30-stage-iv-hodgkin-lymphoma/. 2019.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement. Ann Intern Med. 2009;151(4):264–269.
   PubMed Web of Science ®Google Scholar
• National Institute of Clinical Excellence N. Single technology appraisal: user guide for company evidence submission template. 2017 [cited 2020]. Available from: https://www.nice.org.uk/process/pmg24/chapter/instructions-for-companies.
   Google Scholar
• (CRD). CfRaD. Systematic reviews CRD’s guidance for undertaking reviews in health care 2009 [cited 2020]. Available from: http://www.york.ac.uk/inst/crd/pdf/Systematic_Reviews.pdf
   Google Scholar
• Anselmo AP, Cavalieri E, Enrici RM, et al. Combined modality therapy in advanced Hodgkin’s disease: a report on 218 patients with a median follow-up of eight years. Haematologica. 1998 Jul;83(7):645–650.
   PubMed Web of Science ®Google Scholar
• Arakelyan N, Berthou C, Desablens B, et al. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group. Cancer. 2008 Dec 15;113(12):3323–3330.
   PubMed Web of Science ®Google Scholar
• Aviles A, Neri N, Nambo MJ, et al. Late cardiac toxicity secondary to treatment in Hodgkin’s disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy. Leukemia Lymphoma. 2005;46(7):1023–1028.
   PubMed Web of Science ®Google Scholar
• Ballova V, Ruffer JU, Haverkamp H, et al. A prospectively randomized trial carried out by the German Hodgkin study group (GHSG) for elderly patients with advanced Hodgkin’s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol. 2005 Jan;16(1):124–131.
   PubMed Web of Science ®Google Scholar
• Bjorkholm M, Axdorph U, Grimfors G, et al. Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin’s disease. A prospective randomized trial. Ann Oncol. 1995 Nov;6(9):895–899.
   PubMed Web of Science ®Google Scholar
• Borchmann P, Haverkamp H, Diehl V, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin study group. J Clin Oncol. 2011 Nov 10;29(32):4234–4242.
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin’s disease. A report of 8-year results. Ann Intern Med. 1986 Jun;104(6):739–746.
   PubMed Web of Science ®Google Scholar
• Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992 Nov 19;327(21):1478–1484.
   PubMed Web of Science ®Google Scholar
• Carde P, Karrasch M, Fortpied C, et al. Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, international prognostic score >/= 3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 intergroup trial. J Clin Oncol. 2016 Jun 10;34(17):2028–2036.
   PubMed Web of Science ®Google Scholar
• Casasnovas O, Brice P, Bouabdallah R, et al. Randomized phase III study comparing an early pet driven treatment de-escalation to a not pet-monitored strategy in patients with advanced stages Hodgkin lymphoma: interim analysis of the AHL2011 lysa study. Blood. 2015 Dec 03;126(23):577.
   Web of Science ®Google Scholar
• Chisesi T, Federico M, Levis A, et al. ABVD versus Stanford V versus MEC in unfavourable Hodgkin’s lymphoma: results of a randomised trial. Ann Oncol. 2002;13(SUPPL. 1):102–106.
   PubMed Web of Science ®Google Scholar
• Chisesi T, Bellei M, Luminari S, et al. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin’s lymphoma: a study from the Intergruppo Italiano Linfomi. J Clin Oncol. 2011 Nov 10;29(32):4227–4233.
   PubMed Web of Science ®Google Scholar
• Connors JM, Klimo P, Adams G, et al. Treatment of advanced Hodgkin’s disease with chemotherapy–comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the national cancer institute of Canada clinical trials group. J Clin Oncol. 1997 Apr;15(4):1638–1645.
   PubMed Web of Science ®Google Scholar
• Diehl V, Franklin J, Hasenclever D, et al. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin’s lymphoma: interim report from a trial of the German Hodgkin’s lymphoma study group. J Clin Oncol. 1998 Dec;16(12):3810–3821.
   PubMed Web of Science ®Google Scholar
• Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009 Sep 20;27(27):4548–4554.
   PubMed Web of Science ®Google Scholar
• Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol. 2003 Feb 15;21(4):607–614.
   PubMed Web of Science ®Google Scholar
• Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.[erratum appears in lancet. Lancet. 2012 May 12;379(9828):1791–1799.
   PubMed Web of Science ®Google Scholar
• Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 Gruppo Italiano per lo studio dei linfomi trial. J Clin Oncol. 2009 Feb 10;27(5):805–811.
   PubMed Web of Science ®Google Scholar
• Merli F, Luminari S, Gobbi PG, et al. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: A study by fondazione Italiana Linfomi. J Clin Oncol. 2016;34(11):1175–1181.
   PubMed Web of Science ®Google Scholar
• Ferme C, Lepage E, Brice P, et al. Combined chemotherapy-radiotherapy in advanced Hodgkin’s disease: results of a prospective clinical trial with 70 stage IIIB-IV patients. Int J Radiat Oncol Biol Phys. 1993 Jun 15;26(3):397–405.
   PubMed Web of Science ®Google Scholar
• Glick JH, Young ML, Harrington D, et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin’s disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol. 1998 Jan;16(1):19–26.
   PubMed Web of Science ®Google Scholar
• Gobbi PG, Levis A, Chisesi T, et al. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin’s lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol. 2005 Dec 20;23(36):9198–9207.
   PubMed Web of Science ®Google Scholar
• Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the eastern cooperative oncology group (E2496). J Clin Oncol. 2013 Feb 20;31(6):684–691.
   PubMed Web of Science ®Google Scholar
• Evens AM, Hong F, Gordon LI, et al. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol. 2013 Apr;161(1):76–86.
   PubMed Web of Science ®Google Scholar
• Hoskin PJ, Lowry L, Horwich A, et al. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin’s lymphoma: united kingdom national cancer research institute lymphoma group study ISRCTN 64141244. J Clin Oncol. 2009 Nov 10;27(32):5390–5396.
   PubMed Web of Science ®Google Scholar
• Johnson PW, Radford JA, Cullen MH, et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin’s lymphoma: results of the United Kingdom lymphoma group LY09 Trial (ISRCTN97144519). J Clin Oncol. 2005 Dec 20;23(36):9208–9218.
   PubMed Web of Science ®Google Scholar
• Kriachok IA, Titorenko IB, Novosad OI, et al. Preliminary results of prospective randomized multicentre study ‘beacopp-14 versus beacoppescalated in patients with hodgkins lymphoma from poor-prognosis group’. Hematol Oncol. 2013;31:125–126.
   Google Scholar
• Machiels JP, Ferrant A, Martiat P, et al. A prospective randomized study of two alternating, non cross-resistant chemotherapies for advanced Hodgkin’s disease. Acta Clin Belg. 1992;47(4):244–250.
   PubMed Web of Science ®Google Scholar
• Mounier N, Brice P, Bologna S, et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles > 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol. 2014 Aug 01;25(8):1622–1628.
   PubMed Web of Science ®Google Scholar
• Sieber M, Tesch H, Pfistner B, et al. Treatment of advanced Hodgkin’s disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin’s lymphoma study group HD6 trial. Ann Oncol. 2004 Feb;15(2):276–282.
   PubMed Web of Science ®Google Scholar
• Viviani S, Bonadonna G, Santoro A, et al. Alternating versus hybrid MOPP-ABVD in Hodgkin’s disease: the milan experience. Ann Oncol. 1991;2(2):55–62.
   PubMedGoogle Scholar
• Aviles A, Guzman R, Talavera A, et al. Randomized study for the treatment of adult advanced Hodgkin’s disease: epirubicin, vinblastine, bleomycin, and dacarbazine (EVBD) versus mitoxantrone, vinblastine, bleomycin, and dacarbazine (MVBD). Med Pediatr Oncol. 1994;22(3):168–172.
   PubMedGoogle Scholar
• Aviles A, Cleto S, Neri N, et al. Treatment of advanced Hodgkin’s disease: EBVD versus intensive brief chemotherapy. Leuk Lymphoma. 2003 Aug;44(8):1361–1365.
   PubMed Web of Science ®Google Scholar
• Djeridane M, Oudard S, Escoffre-Barbe M, et al. Treatment of patients with advanced or bulky Hodgkin disease with a 12-week doxorubicin, bleomycin, vinblastine, and dacarbazine-like chemotherapy regimen followed by extended-field, full-dose radiotherapy: long-term results of the groupe ouest et est des leucemies et autres maladies de sang H90-A/B multicenter randomized trial. Cancer. 2002 Nov 15;95(10):2169–2179.
   PubMed Web of Science ®Google Scholar
• Gobbi PG, Broglia C, Berte R, et al. Lomustine and melphalan cannot be replaced by cyclophosphamide and etoposide without reducing efficacy in MOPPEBVCAD chemotherapy for advanced Hodgkin’s disease. Haematologica. 2000 Jul;85(7):722–728.
   PubMed Web of Science ®Google Scholar
• Grozea PN, De Persio EJ, Coltman CA, et al. A southwest oncology group: chemotherapy versus chemotherapy plus radiotherapy in treatment of stage III Hodgkin’s disease. Recent results cancer res Fortschr der Krebsforschung Progrès dans les recherches sur le cancer. 1982;80:83–91.
   PubMedGoogle Scholar
• Hancock BW, Gregory WM, Cullen MH, et al. ChIVPP alternating with PABIOE is superior to PABIOE alone in the initial treatment of advanced Hodgkin’s disease: results of a british national lymphoma investigation/central lymphoma group randomized controlled trial. Br J Cancer. 2001 May 18;84(10):1293–1300.
   PubMed Web of Science ®Google Scholar
• Holte H, Mella O, Wist E, et al. ChlVPP is as effective as alternating ChlVPP/ABOD in advanced stage Hodgkin’s disease. Acta Oncologica. 1996;35(8):73–80.
   PubMedGoogle Scholar
• Longo DL, Duffey PL, DeVita VT, et al. Treatment of advanced-stage Hodgkin’s disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP. J Clin Oncol. 1991 Aug;9(8):1409–1420.
   PubMed Web of Science ®Google Scholar
• Pavlovsky S, Santarelli MT, Muriel FS, et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage III-IV A & B Hodgkin’s disease. Ann Oncol. 1992 Jul;3(7):533–537.
   PubMed Web of Science ®Google Scholar
• Radford JA, Rohatiner AZ, Ryder WD, et al. ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin’s disease. J Clin Oncol. 2002 Jul 1;20(13):2988–2994.
   PubMed Web of Science ®Google Scholar
• Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med. 2011 Jul 21;365(3):203–212.
   PubMed Web of Science ®Google Scholar
• Borchmann P, Goergen H, Kobe C, et al. Treatment reduction in patients with advanced-stage hodgkin lymphoma and negative interim pet: final results of the international, randomized phase 3 trial HD18 by the German hodgkin study group. In: Presidential Symposium:European Hematology Association; 2017June23. Abstract S150
   Google Scholar
• Borchmann P, Goergen H, Kobe C, et al. ebeacopp with or without rituximab in interim-pet-positive advanced-stage Hodgkin lymphoma: updated results of the international, randomized phase 3 GHSG HD18 trial. Hematol Oncol. 2017;35(S2):65.
   Google Scholar
• Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin study group. Lancet. 2017 Oct 20;390(10114):2790–2802.
   PubMed Web of Science ®Google Scholar
• Borchmann P, Haverkamp H, Lohri A, et al. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin’s lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin study group. Lancet Oncol. 2017 Apr;18(4):454–463.
   PubMed Web of Science ®Google Scholar
• Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018 Jan 25;378(4):331–344.
   PubMed Web of Science ®Google Scholar
• Chen R, Ansell S, Gallamini A, et al. Brentuximab vedotin with chemotherapy for stage iii or iv Hodgkin lymphoma: impact of cycle 2 pet result on modified progression-free survival. Abstract PS1172. European Hematology Association 2018 Conference. Sweden. 2018.
   Google Scholar
• Chen RW, Ansell SM, Gallamini A, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): impact of cycle 2 PET result on modified progression-free survival (mPFS). Abstract 7539. 2018 ASCO Annual Meeting. United States. 2018.
   Google Scholar
• Trotman J, Fosså A, Federico M, et al. response-adjusted therapy for advanced Hodgkin lymphoma (Rathl) trial: longer follow up confirms efficacy of de-escalation after a negative interim pet scan (CRUK/07/033). Hematol Oncol. 2017;35(S2):65–67.
   Google Scholar
• Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med. 2016 Jun 23;374(25):2419–2429.
   PubMed Web of Science ®Google Scholar
• Ramchandren R, Advani RH, Ansell SM, et al. Brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma (HL): north American results. J Clin Oncol. 2018;36(15_suppl):7541.
   Google Scholar
• Straus DJ, Collins GP, Walewski JA, et al. Improving outcomes with brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma. J Clin Oncol. 2018;36(15_suppl):7534.
   Web of Science ®Google Scholar
• Hutchings M, Radford J, Gallamini A, et al. Brentuximab vedotin plus chemotherapy in high risk advanced-stage classical Hodgkin lymphoma (CHL) patients: results of pre-specified sub-group analyses from the ECHELON-1 STUDY. European Hematology Association. Abstract S112. Sweden. 2018.
   Google Scholar
• Casasnovas O, Brice P, Bouabdallah R, et al. Final analysis of the AHL2011 randomized phase iii LYSA study comparing an early pet driven treatment de-escalation to a not pet-monitored strategy in patients with advanced stages Hodgkin lymphoma. Abstract S110. European Hematology Association. Sweden. 2018.
   Google Scholar
• Casasnovas O, Brice P, Bouabdallah R, et al. Randomized phase III study comparing an early PET driven treatment de-escalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma: final analysis of the AHL2011 LYSA study. J Clin Oncol. 2018;36(15_suppl):7503.
   Web of Science ®Google Scholar
• Kobe C, Goergen H, Fuchs M, et al. Treatment reduction in patients with advanced-stage Hodgkin lymphoma and negative interim FDG-PET: final results of the international, randomized, phase 3 HD18 trial by the german Hodgkin study group. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 2):S119–S956.
   PubMedGoogle Scholar
• Kreissl SGH, Kobe C, Fuchs M, et al. Treatment reduction in patients with advanced-stage-Hodgkin-lymphoma and negative interim PET: final results of the international randomized phase 3 trial HD18 by the German Hodgkin study group. Abstracts Oncol Res Treat. 2017;40(suppl 3): 1–245. Abstract V684.
   Google Scholar
• Eichenauer DA, Plutschow A, Kreissl S, et al. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin’s lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin study group. Lancet Oncol. 2017 Dec;18(12):1680–1687.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Radford J, Jurczak W, et al. Frontline brentuximab vedotin plus chemotherapy exhibits superior modified progression-free survival vs chemotherapy alone in patients with stage iii or iv Hodgkin lymphoma: phase 3 ECHELON-1 study. European Hematology Association. Abstact PS1182. Sweden. 2018.
   Google Scholar
• Gallamini A, Tarella C, Viviani S, et al. Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: long-term results of the GITIL/FIL HD 0607 trial. J Clin Oncol. 2018 Feb 10;36(5):454–462.
   PubMed Web of Science ®Google Scholar
• von Tresckow B, Kreissl S, Haverkamp H, et al. Beacoppescalated followed by radiotherapy of initial bulk or residual disease in advanced stage Hodgkin lymphoma: long-term follow up of the HD9 and HD12 trials of the German Hodgkin study group. T001. Haematologica: 10th International Symposium on Hodgkin Lymphoma. Germany. 2016.
   Google Scholar
• Aleknavicius E, Valuckas KP, Aleknaviciene B, et al. [Treatment results of Hodgkin’s lymphoma]. [Lithuanian]. [Hodzkino limfomos gydymo rezultatai.]. Medicina (Kaunas). 2009;45(8):615–623.
   PubMed Web of Science ®Google Scholar
• Andjelic BM, Mihaljevic BS, Jakovic LR. ABVD as the treatment option in advanced Hodgkin’s lymphoma patients older than 45 years. Pathol Oncol Res. 2012 Jul;18(3):675–680.
   PubMed Web of Science ®Google Scholar
• Andjelic B, Antic D, Jakovic L, et al. A single institution experience on 314 newly diagnosed advanced Hodgkin lymphoma patients: the role of ABVD in daily practice. Eur J Haematol. 2014 Nov;93(5):392–399.
   PubMed Web of Science ®Google Scholar
• Andrieu JM, Jais JP, Colonna P, et al. Ten-year results of a strategy combining three cycles of ABVD and high-dose extended irradiation for treating Hodgkin’s disease at advanced stages. Ann Oncol. 1998 Feb;9(2):195–203.
   PubMed Web of Science ®Google Scholar
• Belada D, Stepankova P, Sykorova A, et al. Ten years’ experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphoma: A single-center, retrospective study. Leukemia Lymphoma. 2015 Jul 01;56(7):2013–2018.
   PubMed Web of Science ®Google Scholar
• Cabrera ME, Garcia H, Lois V, et al. Hodgkin lymphoma in Chile: experience of the national adult cancer program. [Spanish]. [Linfoma de Hodkin en Chile: experiencia de 15 anos del programa nacional de cancer del adulto.]. Revista Medica De Chile. 2007 Mar;135(3):341–350.
   PubMed Web of Science ®Google Scholar
• Chichoune S, Touati S, Menia H, et al. Outcome of high risk Hodgkin’s lymphoma in the south-EST of Algeria. Haematologica. 2013 Jun 01;98:573.
   Web of Science ®Google Scholar
• Fossa A, Fiskvik IH, Kolstad A, et al. Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis. Ann Oncol. 2012 May;23(5):1254–1259.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Patti C, Viviani S, et al. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol. 2011 Mar;152(5):551–560.
   PubMed Web of Science ®Google Scholar
• Ganesan P, Rajendranath R, Kannan K, et al. Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin’s lymphoma. Ann Oncol. 2015 Jun;26(6):1170–1174.
   PubMed Web of Science ®Google Scholar
• Gupta S, Lapuz C, Holliday E, et al. Excellent prognosis in stage iii and iv Hodgkin lymphoma treated with ABVD with complete response on pet. Hematol Oncol. 2015;33:258.
   Google Scholar
• Haverkamp H, Boll B, Eichenauer DA, et al. Impact of bleomycin and vincristine dose reductions in patients with advanced Hodgkin lymphoma treated with BEACOPP: an analysis of the German Hodgkin study group HD12 and HD15 trials. J Clin Oncol. 2015 Aug 1;33(22):2430–2436.
   PubMed Web of Science ®Google Scholar
• Jain H, Sengar M, Nair R, et al. Treatment results in advanced stage Hodgkins lymphoma: a retrospective study. J Postgrad Med. 2015 Apr 01;61(2):88–91.
   PubMed Web of Science ®Google Scholar
• Jalali A, Ha FJ, Chong G, et al. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era. Ann Hematol. 2016 Apr 01;95(5):809–816.
   PubMed Web of Science ®Google Scholar
• Kedmi M, Apel A, Davidson T, et al. High risk advanced stage Hodgkin lymphoma is well controlled with 2 cycles of escalated beacopp followed by 4 cycles of ABVD in patients who rapidly achieve metabolic CR on interim PET/CT scan. Blood Conference: 56th Annual Meeting of the American Society of Hematology, United States 2018. Abstract. ASH. 2014;124(21):4442.
   Google Scholar
• Lester EP, Petroni GR, Barcos M, et al. Cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) for advanced-stage Hodgkin’s disease: CALGB 8856. Cancer Invest. 2001;19(5):447–458.
   PubMed Web of Science ®Google Scholar
• Markova J, Kahraman D, Kobe C, et al. Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. Leuk Lymphoma. 2012 Jan;53(1):64–70.
   PubMed Web of Science ®Google Scholar
• Miltenyi Z, Barna S, Garai I, et al. Prognostic value of interim and restaging PET/CT in Hodgkin lymphoma. Results of the CHEAP (Chemotherapy effectiveness assessment by PET/CT) study - Long term observation. Neoplasma. 2015;62(4):627–634.
   PubMed Web of Science ®Google Scholar
• Russo F, Corazzelli G, Frigeri F, et al. A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma. Br J Haematol. 2014 Jul;166(1):118–129.
   PubMed Web of Science ®Google Scholar
• Tao YX, Sun SY, Kang SY, et al. Comparison of dose-dense ABVD and standard ABVD in the treatment of early unfavorable and advanced Hodgkin’s lymphoma: A retrospective analysis. J Huazhong Univ Sci Technol Med Sci. 2014 April;34(2):260–264.
   PubMedGoogle Scholar
• Wongso D, Fuchs M, Plutschow A, et al. Treatment-related mortality in patients with advanced-stage Hodgkin lymphoma: an analysis of the german Hodgkin study group. J Clin Oncol. 2013 Aug 1;31(22):2819–2824.
   PubMed Web of Science ®Google Scholar
• Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013 Dec;14(13):1348–1356.
   PubMed Web of Science ®Google Scholar
• Edwards-Bennett SM, Jacks LM, Moskowitz CH, et al. Stanford V program for locally extensive and advanced Hodgkin lymphoma: the memorial sloan-kettering cancer center experience. Ann Oncol. 2010 Mar;21(3):574–581.
   PubMed Web of Science ®Google Scholar
• Gobbi PG, Pieresca C, Ghirardelli ML, et al. Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin’s disease. Blood. 1998 Apr 15;91(8):2704–2712.
   PubMed Web of Science ®Google Scholar
• Gobbi PG, Broglia C, Levis A, et al. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin’s lymphoma: 10-year results, late toxicity, and second tumors. Clin Cancer Res off J Am Assoc Cancer Res. 2006 Jan 15;12(2):529–535.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Williams J, Bartlett NL, et al. Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin’s disease: eastern cooperative oncology group pilot study E1492. J Clin Oncol. 2000 Mar;18(5):972–980.
   PubMed Web of Science ®Google Scholar
• Levis A, Anselmo AP, Ambrosetti A, et al. VEPEMB in elderly Hodgkin’s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol. 2004 Jan;15(1):123–128.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Cocorocchio E, Peccatori F, et al. ChlVPP/ABVVP, a first line ‘hybrid’ combination chemotherapy for advanced Hodgkin’s lymphoma: a retrospective analysis. Br J Haematol. 2004 Jun;125(5):584–589.
   PubMed Web of Science ®Google Scholar
• Saletti P, Zucca E, Gueneau M, et al. ChlVPP/ABV-VP16 hybrid regimen for advanced Hodgkin’s disease: a study in 36 patients. Leukemia Lymphoma. 1999;33(3–4):313–319.
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Hong F, Glick JH, et al. Radiation therapy compared with chemotherapy for consolidation of chemotherapy-induced remission of advanced Hodgkin lymphoma: a study by the eastern co-operative oncology group (E1476) with >20 years follow-up. Leuk Lymphoma. 2009 Oct;50(10):1632–1641.
   PubMed Web of Science ®Google Scholar
• Younes A, Oki Y, McLaughlin P, et al. Phase 2 study of rituximab plusABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood. 2012;119(18):4123–4128.
   PubMed Web of Science ®Google Scholar
• Russo F, Aloj L, Svanera G, et al. Dose-dense/dose-intense ABVD in advanced-stage Hodgkin’s lymphoma: a long-term follow up study. P009. Haematologica: 10th International Symposium on Hodgkin Lymphoma, Cologne, Germany, Oct 22- 25.2016.
   Google Scholar
• Andjelic B, Antic D, Jakovic L, et al. Advanced Hodgkin lymphoma patients without large tumor mass a new prognostic score identifies patients with favourable outcome. PB 1892. 22nd Congress of the European Hematology Association. Spain. 2017.
   Google Scholar
• Carras S, Dubois B, Senecal D, et al. Interim PET response-adapted strategy in untreated advanced stage Hodgkin lymphoma: results of GOELAMS LH 2007 phase 2 multicentric trial. Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):191–198.
   PubMed Web of Science ®Google Scholar
• Damlaj M, Al-Zahrani M, Syed G, et al. Escalation from ABVD following positive interim functional imaging improves progression free survival but not overall survival in advanced classical Hodgkin lymphoma - a real world analysis. Blood. 2017;130(Suppl 1):2799.
   PubMedGoogle Scholar
• Dann EJ, Bairey O, Bar-Shalom R, et al. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients. Br J Haematol. 2017 Sep;178(5):709–718.
   PubMed Web of Science ®Google Scholar
• Evens AM, Hamlin PA, Nabhan C, et al. Sequential brentuximab vedotin and adriamycin, vinblastine, and dacarbazine for older patients with untreated Hodgkin lymphoma: findings from a phase ii window study. P001. Haematologica: 10th International Symposium on Hodgkin Lymphoma. Germany. 2016.
   Google Scholar
• Friedberg JW, Forero-Torres A, Bordoni RE, et al. Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged >/=60 years with HL. Blood. 2017 Dec 28;130(26):2829–2837.
   PubMed Web of Science ®Google Scholar
• C Ea L, O’Brien PC, Capp AL, et al. Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era. Blood Lymphat Cancer. 2018;8:13–20.
   PubMed Web of Science ®Google Scholar
• Marr KC, Connors JM, Savage KJ, et al. ABVD chemotherapy with reduced radiation therapy rates in children, adolescents and young adults with all stages of Hodgkin lymphoma. Ann Oncol. 2017 Apr 1;28(4):849–854.
   PubMed Web of Science ®Google Scholar
• Russell J, Collins A, Fowler A, et al. Advanced Hodgkin lymphoma in the east of England cancer network: A 10-year comparative analysis of outcomes for ABVD and escalated-BEACOPP treated patients aged 16 to 59. Hematol Oncol. 2017;35(S2):318–319.
   Google Scholar
• Zaucha JM, Malkowski B, Chauvie S, et al. The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin’s lymphoma patients-the polish lymphoma research group (PLRG) observational study. Ann Oncol. 2017 Dec 1;28(12):3051–3057.
   PubMed Web of Science ®Google Scholar
• Federico M, Bellei M, Cheson BD. BEACOPP or no BEACOPP? Lancet Oncol. 2013 Nov;14(12):e487–8.
   PubMed Web of Science ®Google Scholar
• Evens AM, Advani RH, Helenowski IB, et al. Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. J Clin Oncol. 2018 Oct 20;36(30):3015–3022.
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012 Jun 20;30(18):2183–2189.
   PubMed Web of Science ®Google Scholar
• Rueda A, Sevilla I, Guma J, et al. Secondary prophylactic G-CSF (filgrastim) administration in chemotherapy of stage I and II Hodgkin’s lymphoma with ABVD. Leuk Lymphoma. 2001 Apr;41(3–4):353–358.
   PubMed Web of Science ®Google Scholar
• Phillippo DM, Ades AE, Dias S, et al. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submission to NICE. 2016 [cited 2020]. Available from http://nicedsu.org.uk/
   Google Scholar
• von Tresckow B, Plutschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin study group HD14 trial. J Clin Oncol. 2012 Mar 20;30(9):907–913.
   PubMed Web of Science ®Google Scholar
• Vakkalanka B, Link BK. Neutropenia and neutropenic complications in ABVD chemotherapy for Hodgkin lymphoma. Adv Hematol. 2011;2011:656013.
   PubMedGoogle Scholar
• Gotti M, Fiaccadori V, Bono E, et al. Therapy-related late adverse events in Hodgkin’s lymphoma. Lymphoma. 2013;2013:7.
   Google Scholar
• Eichenauer DA, Becker I, Monsef I, et al. Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials. Haematologica. 2017 Oct;102(10):1748–1757.
   PubMed Web of Science ®Google Scholar
• van Nimwegen FA, Ntentas G, Darby SC, et al. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood. 2017 Apr 20;129(16):2257–2265.
   PubMed Web of Science ®Google Scholar
• Ng AK, Bernardo MV, Weller E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood. 2002 Sep 15;100(6):1989–1996.
   PubMed Web of Science ®Google Scholar
• Martin WG, Habermann TM, Colgan JP, et al. G-CSF administration increases pulmonary toxicity for Hodgkin’s disease patients treated with bleomycin-containing chemotherapy. Blood. 2004;104(11):1317.
   Web of Science ®Google Scholar
• Aldin A, Umlauff L, Estcourt LJ, et al. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. Cochrane Database Syst Rev. 2019 Sep;16(9):Cd012643.
   Google Scholar
• Amitai I, Gurion R, Vidal L, et al. PET-adapted therapy for advanced Hodgkin lymphoma - systematic review. Acta Oncol. 2018 Jun;57(6):765–772.
   PubMed Web of Science ®Google Scholar